Sanofi Is Aiming For European Accelerated Assessment For Sleeping Sickness Drug

 
• By Francesca Bruce

Sanofi will this week learn whether fexinidazole, the drug the company is developing for sleeping sickness, will be evaluated quickly once it files for approval. The European Medicines Agency’s CHMP is considering this week whether to grant the company’s request for accelerated assessment.

Arrow
Sanofi To Learn If Fexinidazole Wins EU Accelerated Assessment • Source: Shutterstock

More from Product Reviews

More from Pink Sheet